Travis D. Baughan firstname.lastname@example.org
Blue Springs, MO 64014
Montana State University: Dr. Jim Burritt. Bozeman, MT. 2000 -2003.
Undergraduate Research Assistant
Designed a novel approach to bacteriophage epitope mapping resulting in a unique strategy to select a specific
monoclonal antibody required for a project. This work was included in a publication.
Learned and performed molecular biology protocols with minimal oversight.
Trained two undergraduates in plasmid techniques and Western blots.
Lead lab meeting once a year.
Teaching experience: Undergraduate TA for Intro to Microbiology Lab (Spring 2001).
University of Missouri: Dr. Christian Lorson. Columbia, MO. 2003-2008.
Ph.D. Candidate Researcher / Graduate Student Researcher
Chose a high risk anti-sense RNA therapy project and developed it into a Ph.D. thesis and two first author
Added to the scientific knowledge of the RNA processing signals around the alternatively spliced exon found in
the SMN2 gene.
One of the first researchers to add a protein binding domain to anti-sense RNA and to create an RNA with a bi-
partied binding site.
Developed a translational therapy that increased the target protein levels and ameliorated the phenotype in two
mouse models of a neuromuscular disorder.
Implemented rAAV production, titration, and purification for the lab. Trained three graduate students and one
post-doctoral fellow in these techniques.
Trained three undergraduates and two graduate students in cell culture and mouse dissection techniques.
Trained two graduate students in neo-natal I.C.V. injections.
Presented my scientific findings and short- and long-term project goals at lab meeting every 3-4 months.
Lead a journal club meeting every 3-4 months relevant to neurodegeneration.
Teaching experience: Graduate TA for Microbial Pathogenesis Lab (Spring 2003 and 2004).
University of Washington: Dr. Gwenn Garden. Seattle, WA. 2009-2013.
Post-Doctoral Research Fellow
Lead a project describing a growth factor pathway in a neurodegenerative mouse model of Spinocerebellar Ataxia
Type 7 in more detail than previously known.
Further defined the clear and necessary role of a specific cell type in SCA7 neurodegeneration.
Spearheaded the protein diagnostics work in a collaboration with C.H.D.I. (Cure Huntington’s Disease Initiative) to
further describe the same growth factor pathway disruptions in a new Huntington’s disease mouse model .
This project allowed collaborative work with our lab and others both at U. of Washington and elsewhere.
Mouse Colony Manager : Mouse daily monitoring, breeding strategies, transfers, shipments, allocation to all
protocols in lab, supervise two undergraduates helping manage the mouse colony.
Undergraduate Supervisor: At times, up to four undergraduate students; delegated and supervised day-to-day
tasks for projects pertaining to SCA7 and Huntington’s disease; mentored (how many?) in their educational and
Learned and implemented stereotaxic injections and trained two undergraduates in the protocol .
Devised a mouse tissue staining protocol to visualize synaptic terminal coverage.
Designed a behavioral assessment for a mouse model of Alz heimer’s disease.
Trained all new personnel from four joint labs to use and collect data on a Marianas Inverted Microscope.
Presented my current scientific findings and short- and long-term project goals atlab meeting every six months.
cerebellum, brainstem, white matter track, cortex
Molecular Biology :
Use and upkeep of Fluorescent Microscopes
Western blot, PCR, RT-PCR
Preparation of papers, presentations, andgrants
ELISA, Luciferase assay, plasmid cloning, bacterial
and cell transfections, rAAV, Lentivirus purification
Immunohistochemsitry, cell culture Graphpad Prism
Animal Techniques: Endnote
Oral gavage in mice Slidebook 5.0-6.4
assessment of motor behavior in mice Powerpoint
mouse Injections (many routes)
Full sample reclamation via excel files
Non-fixed dissections of HD mice to isolate striatum,
Stimulating Full-length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector, American Society of
Gene Therapy, Baltimore. June 2006
Potential SMA gene therapy; Identification of Optimal Targets for Bifunctional RNAs in vivo, American Society of
Gene Therapy, Boston. June 2008
Stimulating Full-length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector, Life Sciences Week,
University of Missouri-Columbia. March 2005.
Stimulating Full-length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector, Families of Spi nal
Muscular Atrophy Annual International Research Group Meeting. Philadelphia, PA. June 2005.
Therapeutic Strategies for SMA: Modulation of SMN RNA Splicing, Life Sciences Week, University of Missouri -
Columbia. April 2006.
Therapeutic Strategies for SMA: Modulation of SMN RNA Splicing, Health Sciences Day. University of Missouri -
Columbia. October 2006.
Modulating SMN2 pre-mRNA splicing: Optimal targets for Bifunctional RNAs, Life Sciences Week, University of
Missouri-Columbia. April 2007.
Modulating SMN2 pre-mRNA splicing: Optimal targets for Bifunctional RNAs, American Society of Gene Therapy,
Seattle. June 2007.
Potential SMA gene therapy; Identification of Optimal Targets for Bifunctional RNAs in vivo, Life Sciences
Week, University of Missouri-Columbia. April 2008.
Honors and Awards
Irving L. Wiesmen Undergraduate Biomedical Research Scholarship, Montana State University. May 2001.
USP Grant, Montana State University. January 2002.
Graduate Student Award, University of Missouri-Columbia. June 2004.
Travel Award for Families of SMA. June 2005.
NIH Life Sciences Training Grant, NIH/LSC. May 2005-2006.
3 Place Poster Presentation. University of Missouri -Columbia Life Sciences Week. April 2005.
ASGT Travel Award, American Society of Gene Therapy. May 2006.
NIH Life Sciences Training Grant, NIH/LSC. May 2006-2207.
3 Place Poster Presentation. University of Missouri -Columbia Life Sciences Week. April 2007.
GPC Travel Grant, University of Missouri-Columbia. April 2008.
1 Place Poster Presentation, University of Missouri-Columbia Life Sciences Week. April 2008.
Ruth L. Kirschstein NRSA Training Grant( 5 T32 NS 007332-20), University of Washington. June 2009-May 2010.
Montana State University (8/1998- 5/2002): B.S. Microbiology
University of Missouri (6/2003- 12/2008): Ph.D. Molecular Microbiology and Immunology
Doctoral Thesis: Potential Gene Therapy for Spinal Muscular Atrophy (SMA)
University of Washington (3/2009 – present): Post-Doctoral Fellow
Field of Study: IGF-1 pathway Changes in a Mouse Model of Spinocerebellar Ataxia Type 7
Peer-Reviewed Publications (* indicates authors contributed equally)
Burritt JB, Foubert TR, Baniulis D, Lord CI, Taylor RM, Mills JS, Baughan TD, Roos D, Parkos CA, Jesaitis AJ.
Functional Epitope on Human Neutrophil Flavocytochrome b558. Journal o f Immunology, 170 (12) (2003):
Travis Baughan*, Monir Shababi*, Tristan H. Coady, Alexa M. Dickson, Greg Tullis, Christian Lorson.
Stimulating Full-length SMN2 Expression by Delivering Bifunctional RNAs via Viral Vector. Molecular Therapy,
Vol. 14 (2006) : 54-62
Tristan H. Coady, Travis D. Baughan, Monir Shababi, Marco A. Passini, Christian L. Lorson. Development of a
single vector system that enhances trans -splicing of SMN2 transcripts. PLOS, 2008;3(10).
Baughan TD, A. Dickson, E.Osman, F.F. Rose, C. L. Lorson. Delivery of bifunctional RNAs that target an intronic
repressor and increase SMN levels in an animal model of spinal muscular atrophy. HMG, 2009, May 1;
Guyenet SJ, Furrer SA, DamianVM, Baughan TD, La Spada AR, Garden GA. A simple composite phenotype
scoring system for evaluating mouse models of cerebellar ataxia. J Vis. Exp. 2010, May 21; (39).
Furrer SA, Waldherr SM, Mohanachandran MS, Baughan TD, Nguyen KT, Sopher BL, Damian VM, Garden GA,
La Spada AR. Excision of SCA7 transgene expression in a conditional mouse model restores motor function and
prevents cerebellar synaptic reorganization. HMG, 2012, Dec. 18 Epub.
Custer S, Baughan TD, Chen G, Mohanachandran MS, Sopher BL, Ebner T, La Spada AR, Garden GA. Changes in
Climbing Fiber input leads to a loss of trophic support and calcium buffering capacity in Purkinje Cells in an
SCA7 mouse model. In Preparation.
Associate Member, American Society of Gene Therapy (6/2007-2/2009)
Junior Member, American Society of Gene Therapy (5/2006-5/2007)
1) Dr. Gwenn Garden, email@example.com
2) Dr. Richard Morrison, firstname.lastname@example.org
3) Dr. Christian Lorson, email@example.com